Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Febe, van Maldegem"'
Autor:
Alastair Magness, Emma Colliver, Katey S. S. Enfield, Claudia Lee, Masako Shimato, Emer Daly, David A. Moore, Monica Sivakumar, Karishma Valand, Dina Levi, Crispin T. Hiley, Philip S. Hobson, Febe van Maldegem, James L. Reading, Sergio A. Quezada, Julian Downward, Erik Sahai, Charles Swanton, Mihaela Angelova
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The growing scale and dimensionality of multiplexed imaging require reproducible and comprehensive yet user-friendly computational pipelines. TRACERx-PHLEX performs deep learning-based cell segmentation (deep-imcyto), automated cell-type ann
Externí odkaz:
https://doaj.org/article/f61b4b8bd2f54cbd9679706490019396
Autor:
Tanja D de Gruijl, Lilian J Meijboom, Teodora Radonic, Chris Dickhoff, Idris Bahce, Sayed M S Hashemi, Daniela E Oprea-Lager, Ezgi B Ulas, Suresh Senan, Famke L Schneiders, Joris Veltman, David J Heineman, Anne Vrijmoet, Ilias Houda, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Febe van Maldegem, Marieke F Fransen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Background In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borde
Externí odkaz:
https://doaj.org/article/f70d8187e5304db89a6c5551cdddd8e7
Autor:
Febe van Maldegem, Karishma Valand, Megan Cole, Harshil Patel, Mihaela Angelova, Sareena Rana, Emma Colliver, Katey Enfield, Nourdine Bah, Gavin Kelly, Victoria Siu Kwan Tsang, Edurne Mugarza, Christopher Moore, Philip Hobson, Dina Levi, Miriam Molina-Arcas, Charles Swanton, Julian Downward
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
The tumour microenvironment (TME) may change in response to cancer treatments such as KRAS G12C inhibition, with potential implications for combination therapies. Here, the authors provide an antibody panel and workflow for analysing the TME with ima
Externí odkaz:
https://doaj.org/article/c85c11c742864408a99b5e94e13e53db
Autor:
Charles Swanton, William Hill, Emilia Lim, Claudia Lee, Clare Weeden, Marcellus Augustine, Kezhong Chen, Feng-Che Kuan, Fabio Marongiu, Edward Evans, David Moore, Felipe Rodrigues, Febe van Maldegem, Jesse Boumelha, Selvaraju Veeriah, Andrew Rowan, Cristina Naceur-Lombardelli, Takahiro Karasaki, Monica Sivakumar, Deborah Caswell, Ai Nagano, Min Hyung Ryu, Ryan Huff, Shijia Li, Alastair Magness, Alejandro Suarez-Bonnet, Simon Priestnall, Margreet Lüchtenborg, Katrina Lavelle, Joanna Pethick, Steven Hardy, Fiona McRonald, Meng-Hung Lin, Clara Troccoli, Moumita Ghosh, York Miller, Daniel Merrick, Robert Keith, Maise Al Bakir, Chris Bailey, Lao Saal, Yilun Chen, Anthony George, Chris Abbosh, Nnennaya Kanu, Se-Hoon Lee, Nicholas McGranahan, Chistine Berg, Eva Grönroos, Julian Downward, Tyler Jacks, Christopher Carlsten, Ilaria Malanchi, Allan Hackshaw, Kevin Litchfield, Mariam Jamal-Hanjani, James DeGregori
Environmental carcinogenic exposures are major contributors to global disease burden yet how they promote cancer is unclear. Over 70 years ago, the concept of tumour promoting agents driving latent clones to expand was first proposed. In support of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59319a1fd502dd420ee185fca9f68dc0
https://doi.org/10.21203/rs.3.rs-1770054/v1
https://doi.org/10.21203/rs.3.rs-1770054/v1
Autor:
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, Christopher Moore, Sareena Rana, Miriam Llorian Sopena, Philip East, Rachel Ambler, Panayiotis Anastasiou, Pablo Romero-Clavijo, Karishma Valand, Megan Cole, Miriam Molina-Arcas, Julian Downward
Publikováno v:
Science Advances, 8(29):eabm8780. American Association for the Advancement of Science
Mugarza, E, van Maldegem, F, Boumelha, J, Moore, C, Rana, S, Llorian Sopena, M, East, P, Ambler, R, Anastasiou, P, Romero-Clavijo, P, Valand, K, Cole, M, Molina-Arcas, M & Downward, J 2022, ' Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers ', Science Advances, vol. 8, no. 29, eabm8780, pp. eabm8780 . https://doi.org/10.1126/sciadv.abm8780
Mugarza, E, van Maldegem, F, Boumelha, J, Moore, C, Rana, S, Llorian Sopena, M, East, P, Ambler, R, Anastasiou, P, Romero-Clavijo, P, Valand, K, Cole, M, Molina-Arcas, M & Downward, J 2022, ' Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers ', Science Advances, vol. 8, no. 29, eabm8780, pp. eabm8780 . https://doi.org/10.1126/sciadv.abm8780
Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harboring KRAS G12C mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eba7ee317fefd79fc260d98ab44b82c
https://research.vumc.nl/en/publications/8bed69b7-11f1-4db0-bb5b-f054048a8ab8
https://research.vumc.nl/en/publications/8bed69b7-11f1-4db0-bb5b-f054048a8ab8
Autor:
Edurne, Mugarza, Febe, van Maldegem, Jesse, Boumelha, Christopher, Moore, Sareena, Rana, Miriam, Llorian Sopena, Philip, East, Rachel, Ambler, Panayiotis, Anastasiou, Pablo, Romero-Clavijo, Karishma, Valand, Megan, Cole, Miriam, Molina-Arcas, Julian, Downward
Publikováno v:
Science advances. 8(29)
Recently developed KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cd6d4ef021b1fc55cccd62a3fc557b83
https://pubmed.ncbi.nlm.nih.gov/35857848
https://pubmed.ncbi.nlm.nih.gov/35857848
Autor:
Megan Cole, Jesse Boumelha, Miriam Llorian Sopena, Miriam Molina-Arcas, Panos Anastasiou, Sareena Rana, Christopher I. Moore, Febe van Maldegem, Philip East, Julian Downward, Edurne Mugarza, Karishma Valand, Pablo Romero Clavijo, Rachel Ambler
The recent development and approval of KRASG12C inhibitors promises to change profoundly the clinical management of lung cancer patients harbouring KRASG12C mutations. However, early clinical data indicate that acquired drug resistance can frequently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebd4728b44a095dd96a3a4fd4745a56
https://doi.org/10.1101/2021.10.18.464819
https://doi.org/10.1101/2021.10.18.464819
Autor:
Febe van Maldegem, Julian Downward
Publikováno v:
Immunity. 52:14-16
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc17f3f6d5c8e07c8f0bf8021e9ba297
https://doi.org/10.1016/j.immuni.2019.12.013
https://doi.org/10.1016/j.immuni.2019.12.013
Autor:
Mihaela Angelova, Katey Enfield, Alastair Magness, Emma Colliver, Masako Shimato, Claudia Lee, David A. Moore, Febe Van Maldegem, Philip Hobson, Dina Levi, James L. Reading, Crispin T. Hiley, Julian Downward, Erik Sahai, Charles Swanton
Publikováno v:
Cancer Research. 82:6113-6113
Introduction. Studying cell-to-cell variation within the tumour’s native context is crucial for fully understanding tumour heterogeneity and its impact on disease progression and therapy response. Tumour cells and their surrounding stromal cells ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8db54e0b58ebcfe97a22dcdefa5fffd0
https://doi.org/10.1158/1538-7445.am2022-6113
https://doi.org/10.1158/1538-7445.am2022-6113
Autor:
Dina Levi, Nourdine Bah, K. Enfield, Karishma Valand, Emma Colliver, Miriam Molina-Arcas, Philip Hobson, Julian Downward, Febe van Maldegem, Sareena Rana, Edurne Mugarza, Charles Swanton, Christopher I. Moore, Mihaela Angelova, Megan Cole, Victoria Siu Kwan Tsang, Harshil Patel
Mouse models are critical in pre-clinical studies of cancer therapy, allowing dissection of mechanisms through chemical and genetic manipulations that are not feasible in the clinical setting. In studies of the tumour microenvironment (TME), novel hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e25dd7b585d515f3d1b8f8365e3a98cd
https://doi.org/10.21203/rs.3.rs-301541/v1
https://doi.org/10.21203/rs.3.rs-301541/v1